New investment from the Boehringer Ingelheim Venture Fund (BIVF; Germany) will develop a pluripotent cell-based screening platform for the discovery of small molecules that stimulate muscle regeneration. Anagenesis Biotechnologies’ (France) proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology enables the reproducible differentiation of cells in tissues that can give rise to skeletal muscle, tendons and cartilage, amongst others, which are then used to screen small molecule candidates.
Ilka Wicke, Investment Manager at BIVF, said “Anagenesis has a truly different approach to find a solution for muscle regeneration based on its groundbreaking science. This technology could address an important unmet need for patients suffering from genetically based muscle diseases. We are very pleased to support Anagenesis and to collaborate with their highly knowledgeable team.”
High-throughput screening of drug candidates relies on accurate and mimetic models for the best results. Using this platform, Anagenesis hopes to identify future drug candidates for muscle diseases and type 2 diabetes, which act on muscle satellite cells and brown adipocytes, respectively. A second investor was current shareholder Cap Innov’Est (CIE; Strasbourg, France).
Jean-François Rax, Investment Director at Cap Innov’Est, said: “We are very happy that BIVF joins us in this very promising company and we are convinced that together, we will be able to give Anagenesis the means to develop promising drugs that will really benefit the patients.”
This new investment will fund preclinical work into developing a lead candidate for Duchenne muscular dystrophy and will drive the company to complete round A fundraising of at least €15 million in the next 18 months. It has also allowed Anagenesis to move into new premises and acquire new equipment.